Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Di Cataldo is active.

Publication


Featured researches published by A. Di Cataldo.


European Journal of Cancer | 1999

Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology

Claudio Viscoli; Elio Castagnola; Mareva Giacchino; Simone Cesaro; E Properzi; Fabio Tucci; Rossella Mura; Patrizia Alvisi; Giulio Andrea Zanazzo; G Surico; Federico Bonetti; L De Sio; G Izzi; A. Di Cataldo; Ottavio Ziino; F. Massolo; M. Nardi; Nicola Santoro; S Binda

A one-year prospective, multicentre surveillance study on aetiology, main clinical features and outcome of bloodstream infections in children with cancer was conducted in 18 paediatric haematology centres belonging to the Italian Association for Paediatric Haematology and Oncology. A total of 191 bloodstream infections were reported during the study period. Of them, 123 (64%) occurred in neutropenic and 68 (36%) in non-neutropenic patients. Gram-positive cocci caused 45% (85/191) of the episodes, gram-negative rods 41% (78/191), and fungi 9% (18/191). The remaining 5% (10/191) of the episodes were poly-microbial infections. A total of 204 pathogens were isolated (46% gram-positive cocci; 44% gram-negative rods; and 10% fungi). The aetiologic distribution was similar among neutropenic and non-neutropenic patients. A correlation between the infection and the presence of an indwelling central venous catheter was found in 20% (23/114) of the episodes among neutropenic patients and in 55% (23/62) among non-neutropenic patients. Gram-negative micro-organisms were isolated in an unusually high proportion of catheter-related infections (48%). The overall mortality rate from any cause within 30 days from the first positive blood culture was 11%, and was higher among patients who were neutropenic at the onset of the infection than among those who were not neutropenic (15 versus 4%, P = 0.03). In addition, the mortality was significantly higher in recipients of bone marrow transplantation than in patients with acute leukaemia or solid tumour (21, 11 and 6%, respectively) and was also higher in fungaemias and poly-microbial infections (22 and 30%) than in single gram-positive and gram-negative bacteraemias (11 and 6%).


British Journal of Cancer | 2011

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Gudrun Schleiermacher; Jean Michon; A Ribeiro; Gaëlle Pierron; Mosseri; Hervé Rubie; Caroline Munzer; Jean Bénard; N Auger; Combaret; Isabel Janoueix-Lerosey; Adj Pearson; Deborah A. Tweddle; Nick Bown; Mary Gerrard; K Wheeler; Rosa Noguera; Eva Villamón; Adela Cañete; Castel; Bárbara Marques; A de Lacerda; Gian Paolo Tonini; Katia Mazzocco; Raffaella Defferrari; B. De Bernardi; A. Di Cataldo; N. Van Roy; Bénédicte Brichard; Ruth Ladenstein

Background:In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse.Methods:In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enroled in the prospective European INES trials.Results:Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients whose tumours harboured SCA, in the whole population and in trials INES99.1 and INES99.2, in the absence of clinical symptoms (log-rank test, P=0.0001, P=0.04 and P=0.0003, respectively). In multivariate analysis, a SCA genomic profile was the strongest predictor of poorer progression-free survival.Conclusion:In infants with stage 4s MYCN-non-amplified NB, a SCA genomic profile identifies patients who will require upfront treatment even in the absence of other clinical indication for therapy, whereas in infants with localised unresectable NB, a genomic profile characterised by the absence of SCA identifies patients in whom treatment reduction might be possible. These findings will be implemented in a future international trial.


Leukemia | 1999

Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis

L Lo Nigro; G Cazzaniga; A. Di Cataldo; A Pannunzio; E D'Aniello; Giuseppe Masera; Gino Schilirò; Antonio Biondi

Although most relapses of childhood acute lymphoblastic leukemia (ALL) occur 24–36 months after first CR has been achieved, few patients relapse 5 or more years after CR achievement. The assessment of clonality has proved to be useful in determining whether even those very late events represent the reoccurrence of the original clone or alternatively a secondary leukemia. To gain further information on clonal stability in such late relapse, we performed detailed comparative Southern blotting and PCR analyses of TcRδ and TcRγ gene rearrangements in five ALL at presentation and subsequent relapse which occurred more than 5 years after diagnosis. At least one stable rearranged allele of the TcRδ and TcRγ loci was traced in all cases at presentation and clinical relapse despite a wide heterogeneity of the pattern of rearrangements. Our study extends to a larger series of patients previous findings which have sought to analyze the phenomenon of clonal evolution in children relapsed after more than 5 years of CCR. With respect to the potential pitfalls in monitoring minimal residual disease in childhood ALL for the presence of clonal evolution, our results highlight the combination of two target genes (such as TcRγ and TcRδ) as a tool to reduce false negative MRD results.


Journal of Clinical Oncology | 1995

Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.

S. P. Dibenedetto; A. Di Cataldo; Rosalia Ragusa; Concetta Meli; L Lo Nigro

PURPOSE As part of a study on the pharmacokinetics associated with the administration of asparaginase (ASNase) from Erwinia to the CNS, we determined the levels of asparagine in the CSF of children with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS Twenty children received eight standard doses of intramuscular ASNase (10,000 IU/m2) every 3 days as part of induction therapy. In the postremission phase of therapy, the children were randomized to receive either 20 courses of high-dose intramuscular ASNase (25,000 IU/m2) weekly (n = 8) or four courses of standard-dose intramuscular ASNase (10,000 IU/m2) every 3 days (n = 12). RESULTS All patients had detectable levels of L-asparagine in the CSF at the time of diagnosis. The levels of L-asparagine in CSF were undetectable in 15 of 20 (75%) and in seven of 19 (36.8%) children 3 and 5 days, respectively, after administration of standard-dose ASNase. After administration of high-dose ASNase, the levels of L-asparagine in the CSF were undetectable in five (62.5%) and two (25%) of eight children after 3 and 5 days, respectively. CONCLUSION In this study 60% to 70% and 25% to 35% of children had complete depletion of L-asparagine from the CSF after 3 and 5 days, respectively, after administration of both schedules of ASNase from Erwinia. In the remaining patients, administration of ASNase may have resulted in a suboptimal antileukemic effect at the CNS level.


European Journal of Pediatrics | 1994

Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia.

S. P. Dibenedetto; Rosalia Ragusa; A. Sciacca; A. Di Cataldo; Vito Miraglia; Salvatore D'Amico; L Lo Nigro; A. M. Ippolito

A group of 90 patients with acute lymphoblastic leukaemia (ALL) in first continuous complete remission (CCR), admitted in our hospital between January 1986 and September 1992, were tested for the presence of antibodies against hepatitis C virus (HCV), antibodies against hepatitis B virus and antibodies against HIV-1 during maintenance therapy or thereafter. They were compared with a group of 71 children with other malignancies in first CCR who had been diagnosed consecutively from January 1986 to September 1992. No patient with ALL or any other malignancy was found to be positive for hepatitis B surface antigen or HIV-1. HCV-specific antibodies were detected in 28 out of 87 children (32.1%) with ALL and in 4 out of 44 patients (9%) with malignancies other than ALL who had received at least one transfusion of blood or platelets (P<0.01). HCV-specific antibodies were also detected in one out of three untransfused children with ALL but in none of the untransfused children with malignancies other than ALL. HCV-specific seropositivity influenced the management of children with ALL during maintenance therapy. In fact, as a result of abnormal liver function tests, maintenance therapy had to be suspended significantly more often in the case of HCV-seropositive patients with ALL than in HCV-seronegative ones. Despite the high morbidity during maintenance therapy, chronic liver disease (CLD) was uncommon in both groups: five children with ALL (17.2% of HCV-seropositive children) and one child with a malignancy other than ALL (25%) had CLD. If a follow up for a longer period confirms these observations the impact of HCV-related CLD on the quality of life and survival of patients with ALL or other malignancies will probably be minimal.


Annals of Human Genetics | 1997

Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency in south-east Sicily

R. Cittadella; D. Civitelli; I. Manna; N. Azzia; A. Di Cataldo; G. Schiliroa; C. Brancati

In order to explore the nature of glucose‐6‐phosphate dehydrogenase (G6PD) deficiency in south‐east Sicily, we have analysed the G6PD gene in 25 unrelated males with abnormal G6PD activity and/or electrophoretic mobility, by using the analysis of the appropriate PCR‐amplified fragment of DNA and subsequent digestion by appropriate restriction‐enzymes, looking for the presence of certain known G6PD mutations. We amplified the entire G6PD coding sequence into eight fragments, followed by single‐strand conformation polymorphism (SSCP) analysis and sequencing of those individual fragments that were found to be abnormal by SSCP. Through these methods we found a total of twelve G6PD Mediterranean variants with the association of a silent mutation 1311 (also known as polymorphic site Bcl I), one G6PD Mediterranean without this association, four G6PD A− Val 68 and two G6PD Santamaria and five G6PD Chatham. In a subject with normal activity a mutation was found in exon 5, designated as G6PD Sao Borja. This is the first report on the molecular analysis of G6PD mutations in Sicily and we have obtained evidence for four distinct classes of variants.


Oncogene | 2006

Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry

Antonio Acquaviva; L Ciccolallo; R. Rondelli; A. Balistreri; R Ancarola; R Cozza; D Hadjistilianou; S De Francesco; Paolo Toti; Guido Pastore; Riccardo Haupt; Modesto Carli; Nicola Santoro; A. Di Cataldo; A Fiorillo; Paolo Indolfi; Paolo Nucci; A. Sandri; F Porta; A B Porcaro; P. Tamaro; G Morgese

Survivors of retinoblastoma (Rb) are at high risk of dying from second malignant tumour. The occurrence of second malignant neoplasm (SMN) and related mortality in a cohort of 1111 cases from the Italian Retinoblastoma Registry was analysed, considering the possible role of both genetic and iatrogenic causes. Rb patients had a greater than 10-fold excess in overall mortality compared with the general population (standardized mortality ratio (SMR) 10.73, 95% CI 9.00–12.80). Their excess risk attributable to cancers other than Rb was 14.93 95% CI 10.38–21.49). Survivors of hereditary Rb had an SMR for all causes of 16.25 (95% CI 13.20–20.00), whereas their SMR for all cancers was 25.72 (95% CI 17.38–38.07). Survivors of unilateral sporadic Rb had an SMR of 4.12 from all cancers (95% CI 1.55–10.98) and a much higher excess for overall mortality (SMR 13.34, 95% CI 10.74–16.56). As expected, survivors of hereditary Rb had higher mortality from cancers of the bone (SMR 391.90, 95% CI 203.90–753.20) and soft tissue (SMR 453.00, 95% CI 203.50–1008.40), small intestine (SMR 1375.50, 95% CI 344.00–5499.70), nasal cavity (SMR 13.71, 95% CI 1.93–97.35) and cancers of the brain and central nervous system (SMR 41.14, 95% CI 13.2–127.55)


European Journal of Haematology | 2000

Phenotype-genotype correlation in Sicilian patients with Hb H.

Elena Mirabile; Piera Samperi; A. Di Cataldo; Amelia Poli; M. La Spina; Gino Schilirò

Abstract: We studied 15 Sicilian subjects with Hb H disease correlating clinical examinations with hematological and molecular data. Seven different α‐thal mutations were identified: four deletion types (‐‐MED, ‐‐CAL, ‐α3.7, ‐α4.2) and three nondeletion types (αNcolα, αHphα, αCSα). All the patients had a zero‐gene chromosome (‐‐MED or ‐‐CAL), while the third α gene was deleted (‐α3.7, ‐α4.2) or inactive (αNcolα, αHphα, αCSα). In patients with the nondeletion genotype the analysis of hematological values revealed lower levels of RBC and Hb A2 and significantly higher levels of Hb H. The clinical variability was remarkable, ranging from totally asymptomatic conditions, casually diagnosed, to severe thalassemia intermedia with marked hemolytic crises, liver and spleen enlargement and the necessity for frequent transfusions. The genotype did not justify the gravity of the phenotype in every case, and the differences in clinical manifestations, also notable, are not easily explainable in subjects who apparently have the same genotype.


Acta Haematologica | 1993

Low-Grade Haemolysis and Assessment of Iron Status during the Steady State in G6PD-Deficient Subjects

Rosalia Ragusa; A. Di Cataldo; Simone Gangarossa; L Lo Nigro; Gino Schilirò

We evaluated the iron status of 50 Sicilian patients with G6PD deficiency under steady-state conditions and compared our results with those for 50 control patients. We studied haemolysis and iron indices to evaluate the iron balance. These patients could be considered to be at risk of iron overload as a result of increased bone marrow activity. Reticulocytosis and macrocytosis with reduced levels of haptoglobin were found in the G6PD-deficient subjects, both of which are evidence of a moderate haemolysis. Iron status within the normal range, without iron overload or iron deficiency, was found.


Leukemia | 2007

Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation

L Lo Nigro; Laura Sainati; Anna Leszl; Elena Mirabile; Monica Spinelli; Caterina Consarino; A. Di Cataldo; Saverio Magro; Carolyn A. Felix; G Basso

Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation

Collaboration


Dive into the A. Di Cataldo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge